4.3 Article

GORE® Cardioform ASD Occluder experience in transcatheter closure of complex atrial septal defects

Journal

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
Volume 99, Issue 1, Pages E22-E30

Publisher

WILEY
DOI: 10.1002/ccd.29977

Keywords

atrial septal defect; device; interventional cardiac catheterization

Ask authors/readers for more resources

The study evaluated the effectiveness and safety of the GORE Cardioform ASD Occluder in closing complex ASDs at a tertiary referral center, showing that the device is effective and safe for a high percentage of complex ASDs.
Objective To evaluate the GORE (R) Cardioform ASD Occluder (GCO) (WL Gore & Associates, Flagstaff, AZ) device for complex atrial septal defects (ASD) closure. Background Transcatheter ASD closure is still challenging in complex clinical/anatomic settings. This study evaluated the results of GCO in closure of complex ASD in a tertiary referral center. Methods Between January 2020 and March 2021, 72 patients with significant ASD were submitted to transcatheter closure with GCO at our Institution. Based on clinical/anatomic characteristics, they were classified as complex (n = 36, Group I) or simple (n = 36, Group II). We considered as complex, defects with rim deficiency (< 5 mm) other than antero-superior, relatively large (diameter/patient weight > 1.2 or diameter/patient BSA > 20 mm/m(2)) or within a multifenestrated septum. Procedure results and early outcome were compared between the groups. Results Absolute and relative ASD size (20 +/- 4 vs. 15 +/- 3 mm, p < 0.0001; 0.9 +/- 0.3 vs. 0.4 +/- 0.2 mm/kg, p < 0.0001; 23 +/- 7 vs. 12 +/- 5 mm/m(2), p < 0.0001), QP/QS (2.0 +/- 0.8 vs. 1.4 +/- 0.3, p < 0.001), procedure and fluoroscopy times (73 +/- 36 vs. 43 +/- 21 min, p < 0.0001; 16 +/- 9 vs. 9 +/- 4 min, p < 0.0001, procedure feasibility (94.4 vs. 100%, p < 0.0001) and overall complication rate (13.9 vs. 0%, p < 0.0001) were significantly different between the groups. Successful closure of surgical ASDs was achieved in 92% of cases. Complete closure at last follow-up evaluation did not significantly differ between the groups (97.1 vs. 100%, p = NS), as was wireframe fractures rate (49.1% in the overall population), without clinical, EKG and echocardiographic consequences. Conclusions Percutaneous treatment with GCO device is effective and safe in high percentage of complex ASDs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available